Literature DB >> 34255846

Cross-Sectional Assessment of SARS-CoV-2 Viral Load by Symptom Status in Massachusetts Congregate Living Facilities.

Niall J Lennon1, Roby P Bhattacharyya1,2, Michael J Mina1,3,4, Heidi L Rehm1,2,3,5, Deborah T Hung1,2,3,5, Sandra Smole6, Ann Woolley1,3, Eric S Lander1,5,7, Stacey B Gabriel1.   

Abstract

Transmission of coronavirus disease 2019 (COVID-19) from people without symptoms confounds societal mitigation strategies. From April to June 2020, we tested nasopharyngeal swabs by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) from 15 514 staff and 16 966 residents of nursing homes and assisted living facilities in Massachusetts. Cycle threshold (Ct) distributions were very similar between populations with (n = 739) and without (n = 2179) symptoms at the time of sampling (mean Ct, 25.7 vs 26.4; ranges 12-38). However, as local cases waned, those without symptoms shifted towards higher Ct. With such similar viral load distributions, existing testing modalities should perform comparably regardless of symptoms, contingent upon time since infection.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; molecular diagnostics; symptoms; viral load

Mesh:

Year:  2021        PMID: 34255846      PMCID: PMC8420626          DOI: 10.1093/infdis/jiab367

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  1 in total

1.  Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection.

Authors:  Noah J Silverstein; Yetao Wang; Zachary Manickas-Hill; Claudia Carbone; Ann Dauphin; Brittany P Boribong; Maggie Loiselle; Jameson Davis; Maureen M Leonard; Leticia Kuri-Cervantes; Nuala J Meyer; Michael R Betts; Jonathan Z Li; Bruce D Walker; Xu G Yu; Lael M Yonker; Jeremy Luban
Journal:  Elife       Date:  2022-03-11       Impact factor: 8.713

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.